Xeris Biopharma Holdings (XERS) EBT Margin Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) EBT Margin Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1,585.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -177.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -27.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -356.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 436.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -629.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 208.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | -3,107.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,107.00 |
| Mar 31, 2026 | 1,802.00 |
| Dec 31, 2025 | 2,142.00 |
| Sep 30, 2025 | 3,596.00 |
| Jun 30, 2025 | 2,696.00 |
| Mar 31, 2025 | 3,061.00 |
| Dec 31, 2024 | 2,219.00 |
| Sep 30, 2024 | -920.00 |
| Jun 30, 2024 | 2,432.00 |
| Mar 31, 2024 | 476.00 |
| Dec 31, 2023 | 934.00 |
| Sep 30, 2023 | 4,866.00 |
| Jun 30, 2023 | 5,083.00 |
| Mar 31, 2023 | 10,388.00 |
| Dec 31, 2022 | 19,698.00 |
| Sep 30, 2022 | 16,058.00 |
| Jun 30, 2022 | 20,414.00 |
| Mar 31, 2022 | 7,007.00 |
| Dec 31, 2021 | 7,279.00 |
| Sep 30, 2021 | -6,495.00 |